Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
89bio
Biotech
Roche becomes MASH player via $3.5B deal for 89bio, ph. 3 drug
Roche dived into the MASH space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate.
James Waldron
Sep 18, 2025 5:02am
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders
Sep 20, 2024 8:30am
BioMarin builds exec team with biotech vets—Chutes & Ladders
Aug 23, 2024 8:30am
Biogen CMO Maha Radhakrishnan joins Sofinnova—Chutes & Ladders
Aug 9, 2024 8:30am
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Mar 15, 2024 10:55am
Akero's NASH miss drags a few peers down, spurring deja vu
Oct 11, 2023 10:50am
